ArticleBMC primary care2026
The predictive value of complete blood count and the systemic immune-inflammation index (SII) for diagnosing malignancy in patients undergoing colonoscopy.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable Machine Learning Models Based on Blood Cell-Derived Inflammatory Indices for Identifying Colorectal Neoplasia: A Retrospective Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. Delays in diagnosis remain common, and there is ongoing interest in whether routinely available laboratory parameters may provide early signals of increased risk. Systemic inflammatory markers derived from complete blood count, such as the neutrophil–lymphocyte ratio (NLR), monocyte–lymphocyte ratio (MLR), platelet–lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), have been proposed as potential adjunctive biomarkers; however, their diagnostic value in real-world colonoscopy populations remains uncertain.
aimTo explore the discriminatory performance of NLR, MLR, PLR, and SII for identifying malignant findings among patients undergoing colonoscopy.
methodsThis retrospective single-center study included adults who underwent colonoscopy and had a complete blood count performed prior to the procedure between 2014 and 2024. Participants were classified as having benign, premalignant, or malignant findings based on colonoscopy and histopathology reports. Inflammatory indices were calculated and compared across groups. Receiver operating characteristic (ROC) analyses were performed to assess discriminatory performance. Multivariable logistic regression analyses adjusted for age, sex, and hemoglobin were conducted to evaluate independent associations.
resultsAmong the included patients, 53 (18.8%) had malignant and 77 (27.3%) had premalignant findings. Median values of NLR, MLR, PLR, and SII were significantly higher in patients with malignant findings compared with non-malignant groups (p < 0.05). However, discriminatory performance was limited, with AUC values ranging from 0.63 to 0.69. In multivariable analyses, inflammation-based indices showed at most modest independent associations with malignancy after adjustment for age, sex, and hemoglobin.
conclusionsInflammation-based indices derived from routine complete blood count testing demonstrated statistically significant but limited ability to distinguish malignant from non-malignant colonoscopy findings. Given their modest discriminatory performance and limited independent associations, these markers should be regarded as exploratory and hypothesis-generating rather than clinically actionable diagnostic tools. Further prospective, multicenter studies are required to clarify their potential role, if any, in CRC risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.